Agilent Technologies, Inc. (NYSE:A) Receives Consensus Rating of “Buy” from Analysts

Agilent Technologies, Inc. (NYSE:AGet Rating) has earned a consensus recommendation of “Buy” from the sixteen analysts that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $158.23.

Several equities analysts have issued reports on A shares. Stifel Nicolaus dropped their target price on Agilent Technologies from $169.00 to $145.00 and set a “hold” rating on the stock in a research report on Wednesday, February 23rd. SVB Leerink dropped their target price on Agilent Technologies from $175.00 to $145.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 23rd. Bank of America dropped their target price on Agilent Technologies from $179.00 to $160.00 and set a “buy” rating on the stock in a research report on Wednesday, February 23rd. Citigroup dropped their target price on Agilent Technologies from $190.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, February 23rd. Finally, Robert W. Baird dropped their target price on Agilent Technologies from $170.00 to $161.00 in a research report on Wednesday, February 23rd.

Agilent Technologies stock opened at $119.57 on Tuesday. Agilent Technologies has a fifty-two week low of $116.49 and a fifty-two week high of $179.57. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.64 and a current ratio of 2.19. The company has a market capitalization of $35.92 billion, a P/E ratio of 30.35, a PEG ratio of 2.73 and a beta of 1.06. The stock has a 50-day simple moving average of $130.64 and a 200-day simple moving average of $143.23.

Agilent Technologies (NYSE:AGet Rating) last posted its earnings results on Tuesday, February 22nd. The medical research company reported $1.21 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.17 by $0.04. The business had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.66 billion. Agilent Technologies had a return on equity of 27.04% and a net margin of 18.70%. The business’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.06 EPS. As a group, analysts forecast that Agilent Technologies will post 4.86 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 27th. Investors of record on Tuesday, April 5th were paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date was Monday, April 4th. Agilent Technologies’s payout ratio is currently 21.32%.

In other Agilent Technologies news, SVP Michael Tang sold 1,210 shares of the stock in a transaction on Friday, March 18th. The stock was sold at an average price of $136.21, for a total transaction of $164,814.10. The sale was disclosed in a document filed with the SEC, which is available at this link.

Several institutional investors have recently modified their holdings of A. Ironwood Wealth Management LLC. lifted its stake in shares of Agilent Technologies by 142.5% during the 2nd quarter. Ironwood Wealth Management LLC. now owns 485 shares of the medical research company’s stock worth $72,000 after purchasing an additional 285 shares during the period. Morgan Stanley increased its holdings in shares of Agilent Technologies by 2.9% during the 2nd quarter. Morgan Stanley now owns 1,154,775 shares of the medical research company’s stock worth $170,688,000 after buying an additional 33,059 shares during the last quarter. Lincoln National Corp increased its holdings in shares of Agilent Technologies by 5.8% during the 3rd quarter. Lincoln National Corp now owns 1,838 shares of the medical research company’s stock worth $290,000 after buying an additional 100 shares during the last quarter. Advisor Group Holdings Inc. increased its holdings in shares of Agilent Technologies by 4.3% during the 3rd quarter. Advisor Group Holdings Inc. now owns 65,055 shares of the medical research company’s stock worth $10,245,000 after buying an additional 2,679 shares during the last quarter. Finally, Resources Investment Advisors LLC. increased its holdings in shares of Agilent Technologies by 44.1% during the 3rd quarter. Resources Investment Advisors LLC. now owns 2,674 shares of the medical research company’s stock worth $421,000 after buying an additional 818 shares during the last quarter.

Agilent Technologies Company Profile (Get Rating)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

Further Reading

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.